A dual SGLT1 and SGLT2 inhibitor, sotagliflozin (Inpefa) has also gotten FDA approval for heart failure. "Given that there are extremely robust randomized trial data suggesting very comparable ...

a dual SGLT1/2 inhibitor, reduces cardiovascular events in people with diabetic kidney disease — ischemic benefits not observed in trials of selective SGLT2 inhibitors. Medscape Medical News ...

The European Medicines Agency (EMA) drugs advisory panel has recommended the oral SGLT1/2 inhibitor as an ... type 1 diabetes after AstraZeneca’s SGLT2 inhibitor Forxiga (dapagliflozin), which ...

Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 ...

Preoperative SGLT2 inhibitor use was not associated with an increased risk for postoperative diabetic ketoacidosis among patients with type 2 diabetes. Use of sodium-glucose cotransporter 2 ...

SGLT2 inhibitors are medications designed to help manage blood sugar in people living with type 2 diabetes. Learn more about the different types, as well as the benefits and side effects.

SGLT2 inhibitors are a new family of agents ... transporters located at the brush border of tubular cells (SGLT2 and SGLT1) and the GLUTs facilitated diffusion glucose transporters located ...

Tim Hennigan and Peter Atlas are tired of the political divisiveness, unstable international relations, and Teslas parked in front of the White House. Most of all, they are fed up with President ...

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less ...

Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 (TYK2) inhibitor as a dermatology treatment in Japan. The drug in ...